Journal
MEDCHEMCOMM
Volume 2, Issue 10, Pages 982-986Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c1md00138h
Keywords
-
Funding
- Cancer Therapeutics CRC under Australian Government
- NHMRC IRIISS [361646]
- Victorian State Government
Ask authors/readers for more resources
7-Phenyl-4-aminobenzothieno[3,2-d]pyrimidines were previously reported to exhibit moderate LIMK1 inhibition. Further exploration of SAR around the 7-phenyl moiety has led to the development of a lead series with an increased potency for LIMK1. Evaluation of physicochemical and ADME properties, and off-target kinase screens has seen this novel series emerge as a promising platform for a set of tool compounds for evaluating LIMK as a therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available